Adbiotech Partners with M2Wenty to Jointly Develop Healthcare Products, Targeting Pet and Senior Markets

Adbiotech has partnered with digital healthcare company M2Wenty to jointly develop and commercialize healthcare products utilizing mid- and low-frequency complex stimulation technology. The two companies plan to expand into both domestic and international markets, focusing on pet and senior healthcare, while also broadening their partnership to include equity investment and potential mergers in the future.

On August 28, Adbiotech announced that it had signed a memorandum of understanding with M2Wenty to commercialize products based on mid- and low-frequency complex stimulation technology and to broaden their market reach both in Korea and abroad.

Under this agreement, Adbiotech will take on exclusive domestic and international distribution rights for M2Wenty’s pet product ‘Mayopet’. The two companies also plan to collaborate on developing additional products aimed at not only pets but also large animals.

Adbiotech will participate in clinical trials for healthcare devices currently being developed by M2Wenty. Adbiotech plans to invest in the clinical trial costs for several devices: a device to alleviate side effects from glucagon-like peptide-1 (GLP-1) class anti-obesity drugs, a growth plate stimulator, and a device for treating sarcopenia in people aged 65 and older.

The intellectual property rights generated from these clinical results will be jointly held by both companies. For sarcopenia treatment devices set to be supplied to senior welfare centers in Gangwon Special Self-Governing Province, both parties will share production costs and business profits.

M2Wenty is developing muscle health management solutions based on its mid-frequency technology, "Core Muscle Booster (CMB)". CMB stimulates deep muscles using mid-frequency waves in the range of 2,000 to 6,000 Hertz (Hz), with the aim of strengthening muscles without the need for high-intensity workouts or additional muscle load.

Through this partnership, the two companies plan to expand the scope of collaboration from the distribution of pet healthcare products to clinical trials, production, and ultimately global business. In particular, by combining Adbiotech’s distribution and commercialization capabilities with M2Wenty’s mid- and low-frequency technology, they aim to secure new growth engines.

A representative from Adbiotech stated, “Starting with the domestic and international distribution of Mayopet, we will broaden our cooperation to clinical trials, production, and global business, thereby laying the groundwork for new growth encompassing both pet and senior healthcare.”

The representative added, “We are also considering mid- to long-term cooperation options, including potential equity investment and merger.”

This content was produced with the assistance of AI translation services.